Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Ameile (aumolertinib)
i
Other names:
EQ 143, HS10296, HS-10296, HS 10296, EQ143, EQ-143
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(39)
News
Trials
Company:
Abdul Latif Jameel Health, Jiangsu Hansoh Pharma
Drug class:
EGFR inhibitor
Related drugs:
‹
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
NX-019 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
TY-9591 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
NX-019 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
TY-9591 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
›
Associations
(39)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
aumolertinib
Sensitive: A1 - Approval
aumolertinib
Sensitive
:
A1
aumolertinib
Sensitive: A1 - Approval
aumolertinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
bevacizumab + aumolertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + aumolertinib
Sensitive
:
C2
bevacizumab + aumolertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + aumolertinib
Sensitive
:
C2
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
bevacizumab + aumolertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + aumolertinib
Sensitive
:
C2
bevacizumab + aumolertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + aumolertinib
Sensitive
:
C2
EGFR L858R
Lung Adenocarcinoma
EGFR L858R
Lung Adenocarcinoma
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
aumolertinib + HS-10241
Sensitive: C2 – Inclusion Criteria
aumolertinib + HS-10241
Sensitive
:
C2
aumolertinib + HS-10241
Sensitive: C2 – Inclusion Criteria
aumolertinib + HS-10241
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
anlotinib + aumolertinib
Sensitive: C2 – Inclusion Criteria
anlotinib + aumolertinib
Sensitive
:
C2
anlotinib + aumolertinib
Sensitive: C2 – Inclusion Criteria
anlotinib + aumolertinib
Sensitive
:
C2
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
anlotinib + aumolertinib
Sensitive: C2 – Inclusion Criteria
anlotinib + aumolertinib
Sensitive
:
C2
anlotinib + aumolertinib
Sensitive: C2 – Inclusion Criteria
anlotinib + aumolertinib
Sensitive
:
C2
EGFR positive
Non Small Cell Lung Cancer
EGFR positive
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
EGFR exon 19 deletion + TP53 mutation + MET amplification
Non Small Cell Lung Cancer
EGFR exon 19 deletion + TP53 mutation + MET amplification
Non Small Cell Lung Cancer
bevacizumab + aumolertinib
Sensitive: C3 – Early Trials
bevacizumab + aumolertinib
Sensitive
:
C3
bevacizumab + aumolertinib
Sensitive: C3 – Early Trials
bevacizumab + aumolertinib
Sensitive
:
C3
TP53 mutation
Non Small Cell Lung Cancer
TP53 mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
icotinib + aumolertinib
Sensitive: C3 – Early Trials
icotinib + aumolertinib
Sensitive
:
C3
icotinib + aumolertinib
Sensitive: C3 – Early Trials
icotinib + aumolertinib
Sensitive
:
C3
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
icotinib + aumolertinib
Sensitive: C3 – Early Trials
icotinib + aumolertinib
Sensitive
:
C3
icotinib + aumolertinib
Sensitive: C3 – Early Trials
icotinib + aumolertinib
Sensitive
:
C3
PD-L1 underexpression + EGFR mutation
Non Small Cell Lung Cancer
PD-L1 underexpression + EGFR mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
PD-L1 expression + EGFR mutation
Non Small Cell Lung Cancer
PD-L1 expression + EGFR mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR mutation + PIK3CA mutation
Non Small Cell Lung Cancer
EGFR mutation + PIK3CA mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR mutation + TP53 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR G719X + EGFR L861Q + EGFR S768I
Non Small Cell Lung Cancer
EGFR G719X + EGFR L861Q + EGFR S768I
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR mutation + MET amplification
Non Small Cell Lung Cancer
EGFR mutation + MET amplification
Non Small Cell Lung Cancer
aumolertinib + HS-10241
Sensitive: C3 – Early Trials
aumolertinib + HS-10241
Sensitive
:
C3
aumolertinib + HS-10241
Sensitive: C3 – Early Trials
aumolertinib + HS-10241
Sensitive
:
C3
EGFR L858R + EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR L858R + EGFR exon 19 deletion
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR L858R + EGFR exon 21 deletion
Non Small Cell Lung Cancer
EGFR L858R + EGFR exon 21 deletion
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR mutation + TP53 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation
Non Small Cell Lung Cancer
bevacizumab + aumolertinib
Sensitive: C3 – Early Trials
bevacizumab + aumolertinib
Sensitive
:
C3
bevacizumab + aumolertinib
Sensitive: C3 – Early Trials
bevacizumab + aumolertinib
Sensitive
:
C3
EGFR T790M negative
Non Small Cell Lung Cancer
EGFR T790M negative
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
aumolertinib
Sensitive: C3 – Early Trials
aumolertinib
Sensitive
:
C3
EGFR L858R + EGFR T790M
Lung Adenocarcinoma
EGFR L858R + EGFR T790M
Lung Adenocarcinoma
aumolertinib
Sensitive: C4 – Case Studies
aumolertinib
Sensitive
:
C4
aumolertinib
Sensitive: C4 – Case Studies
aumolertinib
Sensitive
:
C4
EGFR exon 19 deletion + PD-L1 overexpression
Lung Adenocarcinoma
EGFR exon 19 deletion + PD-L1 overexpression
Lung Adenocarcinoma
aumolertinib
Sensitive: C4 – Case Studies
aumolertinib
Sensitive
:
C4
aumolertinib
Sensitive: C4 – Case Studies
aumolertinib
Sensitive
:
C4
EGFR L858R
Glioblastoma
EGFR L858R
Glioblastoma
anlotinib + temozolomide + aumolertinib
Sensitive: C4 – Case Studies
anlotinib + temozolomide + aumolertinib
Sensitive
:
C4
anlotinib + temozolomide + aumolertinib
Sensitive: C4 – Case Studies
anlotinib + temozolomide + aumolertinib
Sensitive
:
C4
EGFR exon 21 mutation
Lung Adenocarcinoma
EGFR exon 21 mutation
Lung Adenocarcinoma
aumolertinib
Sensitive: C4 – Case Studies
aumolertinib
Sensitive
:
C4
aumolertinib
Sensitive: C4 – Case Studies
aumolertinib
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login